Alnylam Pharmaceuticals Unveils 2024 Corporate Responsibility Report, Showcasing Impact Across ESG Pillars Alnylam Pharmaceuticals, the industry leader in RNA interference (RNAi) therapeutics, has published its 2024 Corporate Responsibility Report, reaffirming…
BioNTech Strengthens Partnership with UK Government to Significantly Expand Regional Research and Development Efforts BioNTech , a leading biotechnology firm recognized globally for its pioneering work in mRNA technology and…
CRISPR Breakthrough in a Single Infant Sheds Light on the Urgent Crisis Facing Millions with Ultra-Rare Diseases A groundbreaking success story involving a custom-made CRISPR gene-editing therapy has given new…
Merck and imec Forge Strategic Alliance to Revolutionize Drug Discovery Through Advanced Microphysiological Systems Merck, a global leader in science and technology, and imec, a premier international hub for research…
Aetna Better Health of Illinois Invests $20.4 Million to Strengthen Value-Based Care and Improve Health Equity Across the State Aetna Better Health® of Illinois, a Medicaid managed care plan and…
Roche Provides Update on FDA Advisory Committee Review of Columvi Combination Therapy for Relapsed or Refractory DLBCL Roche has shared an important regulatory update concerning its investigational treatment for a…
FDA Grants Limited Approval to Novavax COVID-19 Vaccine Amid Signs of Upcoming Changes to Vaccine Approval Process The recent decision by the U.S. Food and Drug Administration (FDA) to grant…
GSK Secures Japanese Approval for Blenrep Combinations in Relapsed/Refractory Multiple Myeloma Based on Robust Phase III Data In a major advancement for the treatment landscape of multiple myeloma, GSK plc…
Regeneron to Acquire Core Assets of 23andMe for $256 Million in Bankruptcy Auction, Pledges to Preserve Consumer Genetics Mission and Strengthen Human Health Research In a major development within the…
BATURA Phase IIIb Trial Establishes Airsupra as a New Standard for As-Needed Asthma Rescue Treatment AstraZeneca has released the full results from its pivotal BATURA Phase IIIb trial, revealing that…
Daiichi Sankyo and Merck Launch Phase 3 IDeate-Esophageal01 Trial of Ifinatamab Deruxtecan in Advanced Esophageal Squamous Cell Carcinoma Daiichi Sankyo and Merck have officially initiated dosing in their pivotal Phase…
Cytokinetics Issues Equity Awards as Employment Inducements Under Nasdaq Rule 5635(c)(4), Advances Momentum in Cardiovascular Drug Development Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company dedicated to developing novel therapies…